fda2WASHINGTON, D.C. (5/15/13) - The U.S. Food and Drug Administration today approved Xofigo (radium Ra 223 dichloride) to treat men with symptomatic late-stage (metastatic) castration-resistant prostate cancer that has spread to bones but not to other organs. It is intended for men whose cancer has spread after receiving medical or surgical therapy to lower testosterone.

Prostate cancer forms in a gland in the male reproductive system found below the bladder and in front of the rectum. The male sex hormone testosterone stimulates the prostate tumors to grow. According to the National Cancer Institute, an estimated 238,590 men will be diagnosed with prostate cancer and 29,720 will die from the disease in 2013.

Xofigo is being approved more than three months ahead of the product’s prescription drug user fee goal date of Aug. 14, 2013, the date the agency was scheduled to complete review of the drug application. The FDA reviewed Xofigo under the agency’s priority review program, which provides for an expedited review of drugs that appear to provide safe and effective therapy when no satisfactory alternative therapy exists, or offer significant improvement compared to marketed products.

“Xofigo binds with minerals in the bone to deliver radiation directly to bone tumors, limiting the damage to the surrounding normal tissues,” said Richard Pazdur, M.D., director of the Office of Hematology and Oncology Products in the FDA’s Center for Drug Evaluation and Research. “Xofigo is the second prostate cancer drug approved by the FDA in the past year that demonstrates an ability to extend the survival of men with metastatic prostate cancer.”

In August 2012, the FDA approved Xtandi to treat men with metastatic castration-resistant prostate cancer that has spread or recurred, even with medical or surgical therapy to minimize testosterone. Xtandi is approved for patients who have previously been treated the chemotherapy drug docetaxel.

Xofigo’s safety and effectiveness were evaluated in a single clinical trial of 809 men with symptomatic castration-resistant prostate cancer that spread to bones but not to other organs. Patients were randomly assigned to receive Xofigo or a placebo plus best standard of care.

The study was designed to measure overall survival. Results from a pre-planned interim analysis showed men receiving Xofigo lived a median of 14 months compared to a median of 11.2 months for men receiving placebo. An exploratory updated analysis conducted later in the trial confirmed Xofigo’s ability to extend overall survival.

The most common side effects reported during clinical trials in men receiving Xofigo were nausea, diarrhea, vomiting and swelling of the leg, ankle or foot. The most common abnormalities detected during blood testing included low levels of red blood cells (anemia), lymphocytes (lymphocytopenia), white blood cells (leukopenia), platelets (thrombocytopenia) and infection-fighting white blood cells (neutropenia).

Xofigo is marketed by Wayne, N.J.-based Bayer Pharmaceuticals. Xtandi is co-marketed by Astellas Pharma U.S., Inc. of Northbrook, Ill., and Medivation, Inc. of San Francisco, Calif.
 
SurfKY News
Information provided by the United States Food and Drug Administration

LIKE SurfKY on Facebook - Click here to LIKE us now.

© Copyright 2015 SurfKY News Group, Inc. All rights reserved. This material may not be published, broadcast, or rewritten without permission. SurfKY News encourages you to share this story on social media.

Posted on 2/2/14
3/13 - 16
1 DOW 17,678.23
-40.31 (-0.23%)    
2 S&P 2,056.15
-4.90 (-0.24%)    
3 NASDAQ 4,863.36
-13.16 (-0.27%)    
3/13 - 16

Most Read This Week

March 18, 2015 9391

UPDATE: Hanson Man Located in Henderson, Taken to…

by Trooper Stu Recke
March 18, 2015 6749

UPDATE: Name of Pedestrian Killed on Western…

by Trooper Stu Recke
March 24, 2015 4807

One Dies, Another Injured in Mortons Gap Traffic…

by Deputy Heath Owens
March 25, 2015 4632

Fazoli's, Roses Coming to Madisonville

by Amber Averitt, SurfKY News
March 25, 2015 4628

Grand Jury Finds No Criminal Wrongdoing in Bean…

by Doreen Dennis, SurfKY News
March 24, 2015 3955

UPDATE: One Injured in Hopkinsville Road Accident

by Doreen Dennis, SurfKY News

Most Read This Month

February 25, 2015 13741

Multi-Agency Investigation Nets Large-Scale Meth…

by Trooper Stu Recke
March 09, 2015 12747

Multi-Agency Drug Bust Results in $1 Million Meth…

by KSP DESI

Stories Trending Today

March 25, 2015 4632

Fazoli's, Roses Coming to Madisonville

by Amber Averitt, SurfKY News
March 25, 2015 4628

Grand Jury Finds No Criminal Wrongdoing in Bean…

by Doreen Dennis, SurfKY News
March 25, 2015 3505

Madisonville Man's Living Room Leap Lands Him in…

by Madisonville Police Department / Hopkins County Detention Center
March 25, 2015 2960

Rep Brent Yonts' Letter to TVA concerning…

by Brent Yonts
March 25, 2015 2186

Alleged Speeding in School Zone Ends in DUI Arrest

by Madisonville Police Department / Hopkins County Detention Center
March 25, 2015 1520

Crime Stoppers Fugitive of the Week – March 25,…

by Hopkinsville – Christian County Crime Stoppers
March 25, 2015 1481

Greenville Man Charged with Theft of Vehicle

by Wes Miller
March 26, 2015 1226

‘Chasing Rainbow’ Heart Walk Raises Funds for AHA

by Tammy Holloway, SurfKY News
March 25, 2015 1207

Madisonville Police Arrest Reports - March 25,…

by Madisonville Police Department
March 25, 2015 1145

Hopkins County Sheriff's Reports Released

by Hopkins County Sheriff's Office